The gene synthesis market is set to witness its growth owing to the increased applications in synthetic biology, advancements in genomics research, and the rising need for bespoke DNA constructs for drug development, diagnostics, agriculture, and industrial biotechnology. Gene synthesis enables synthetic construction of gene sequences without any DNA template, thus allowing faster, more precise, and scalable genetic engineering.
The use of gene synthesis in vaccinomics, CRISPR-based gene editing, engineering of metabolic pathways, and synthetic genomes is expected to expand its scope within the academic, pharmaceutical, and biotech sectors. Among other things, the market is benefitted from decreasing prices associated with DNA synthesis, full-scale automation in oligonucleotide assembly, and the application of AI for sequence optimization.
The gene synthesis market is projected to grow at a CAGR of 19%, rising from USD 1,089.3 million in 2025 to approximately USD 6,203.6 million by 2035.
Key Market Metrics
| Metric | Value |
|---|---|
| Market Size in 2025 | USD 1,089.3 million |
| Projected Market Size in 2035 | USD 6,203.6 million |
| CAGR (2025 to 2035) | 19% |
North America records the highest penetration of the gene synthesis market ever conceivable furnished by a vibrant biotechnology setting, sound presence for R&D funding, and numerous applications in precision medicine and synthetic biology.
The United States is the country's leader in gene synthesis services, fueled by the demand from academic laboratories, biopharma companies, and research programs funded by the government.
WHO states, North America's investment into genomics and next-generation biomanufacturing remains a continuing spur of progress in synthetic gene design, particularly for therapeutic and diagnostic development.
Gene synthesis is a stronghold of Europe, and Germany, the UK, and Switzerland are bone fides of genomics, biopharmaceutical inventions, and bioengineering. Support by the EU of life sciences and the demand for personalized medicine and functional genomics continue to push market growth. WHO states that Europe's synthetic biology strategies are enabling cross border collaborations for genome engineering and sustainable biotechnological solutions.
The fastest-growing region, Asia-Pacific, is boosted by increasing activity in genomics research generating biotech start-ups and public-private investments in synthetic biology. China, Japan, South Korea, and India are rapidly establishing gene synthesis capabilities for vaccines, agriculture, and regenerative medicine.
UN predicts that the Asia-Pacific has a burgeoning role in global biomanufacturing and genetic engineering by 2035, with affordable service offerings and local innovation driving its spillover effect.
Regulatory ambiguity, biosafety, and IP issues
The lack of globally harmonized regulations for synthetic gene production and distribution raises moral dilemmas related to biosecurity and dual-use technologies and interfere with cross-border control of gene-edited constructs. Differing quality standards may also promote variability in the reproducibility of research.
The Intellectual Property Rights disputes surrounding synthetic gene sequences and oligo assembling technologies could restrict collaborations among entities and slow product development. According to WHO, biosafety and governance challenges must be addressed to foster equitable, just, and secure practices of gene synthesis all over the globe.
Growth of synthetic biology, development of therapeutic agents, and design using AI
This increases the growing demand for fast, accurate, scalable gene synthesis services by applications in synthetic biology across healthcare-related industries and agriculture-biotechnology and industrial biotech. Promotional areas include custom gene libraries for antibody discovery, synthetic vaccine design, and biosynthetic pathway optimization.
These technologies are incorporated within gene synthesis pipelines being used for codon optimization, error minimization, and de novo genome design. The use of engineered, synthetic DNA for therapeutic development and preparedness strategies in the long run through pandemics above all demonstrate the strategic value gene synthesis holds in the global security arena.
In the period 2020 to 2024, gene synthesis will maintain the momentum gained due to its critical contributions to mRNA vaccine construction, rapid prototyping of therapeutic constructs, and research genomics in academic circles. The pandemic of COVID-19 hastened synthetic biology investments and fast-tracked pathogen surveillance.
The years from 2025 to 2035 will be ushered in by a shift of the market toward automated, cloud-based synthesis platforms, which offer real-time tracking of sequences, scalable manufacturing, and integration into digital health records. Such developments include the DNA data storage system, the synthetic minimal genomes, and on-demand biofabrication, which will inform the future of gene synthesis applications.
Market Shifts: A Comparative Analysis 2020 to 2024 vs. 2025 to 2035
| Market Shift | 2020 to 2024 Trends |
|---|---|
| Regulatory Landscape | Emergency use of synthetic genes in vaccine research |
| Consumer Trends | Interest in rapid-response genetic tools |
| Industry Adoption | Biopharma and academic labs |
| Supply Chain and Sourcing | Centralized gene synthesis facilities |
| Market Competition | Led by synthetic biology firms and contract manufacturers |
| Market Growth Drivers | Vaccine development and CRISPR research |
| Sustainability and Impact | Energy- and reagent-intensive workflows |
| Smart Technology Integration | Manual sequence input and email-based tracking |
| Sensorial Innovation | N/A (non-sensorial product) |
| Market Shift | 2025 to 2035 Projections |
|---|---|
| Regulatory Landscape | Standardized biosecurity frameworks and cross-border DNA governance |
| Consumer Trends | Demand for personalized gene libraries and therapeutic-grade constructs |
| Industry Adoption | Expansion into agriculture, biomanufacturing, and consumer biotech |
| Supply Chain and Sourcing | Distributed biofoundries and near-site micro-synthesis units |
| Market Competition | Entry of AI-driven platforms and cloud-based design services |
| Market Growth Drivers | Bio-based economy, DNA data storage, and personalized medicine |
| Sustainability and Impact | Enzyme-free synthesis, recyclable materials, and green biotech practices |
| Smart Technology Integration | API-driven synthesis, AI optimization, and blockchain-enabled traceability |
| Sensorial Innovation | Visual dashboards, real-time sequence validation, and quality scoring |
The gene synthesis market in the United States is enjoying strong growth propelled by significant demand in synthetic biology, personalized medicine, and other biologics development. Gene synthesis is most commonly used to construct vaccines, enzyme engineering applications, and CRISPR-based therapeutics in most academic research institutes, biotechnological companies, and pharmaceutical corporations.
As the OECD puts it, the USA leads the world in genomics R&D investment, bolstered by initiatives from NIH, DARPA, and others to boost speed and yield in gene-based solutions. For example, custom genes benefit from cloud-based ordering platforms and automation in DNA assembly, which increases accessibility and lowers turnaround times.
| Country | CAGR (2025 to 2035) |
|---|---|
| United States | 19.3% |
The gene synthesis market in the UK is rapidly expanding through strong academic-industry collaboration and support for bio-innovation under the UK Life Sciences Vision. More applications of gene synthesis include the development of vaccines, agricultural biotechnology, and research in cell therapies.
According to OECD, public investment in synthetic biology hubs is facilitating the development of new products, especially in areas such as antimicrobial resistance and green bio-manufacturing. Demand for high-throughput DNA synthesis for gene editing and metabolic pathway engineering boosts growth.
| Country | CAGR (2025 to 2035) |
|---|---|
| United Kingdom | 18.7% |
The emergence of the European gene synthesis market is characterized by contribution from Germany, France, and the Netherlands, where interlinked biotech clusters contribute to developing industrial enzymes, biopharmaceuticals, and sustainable materials.
According to UN, Horizon Europe funding is providing resources for genomic engineering and gene circuit design, enhancing opportunities for innovations at both academic and commercial levels. The direction taken by the green biotechnology shift and climate-friendly solutions further increases the demand for synthetic gene pathways. Biosecurity and ethical standards for the European Union also set the guide in safe and responsible expansion of the market.
| Country | CAGR (2025 to 2035) |
|---|---|
| European Union | 19.0% |
Japan's gene synthesis market is stabilizing and growing. Applications are in regenerative medicine, vaccine development, and agricultural biotechnology. Synthetic genes are used for stem cell research and the generation of therapeutic proteins at both universities and life sciences companies.
At present, as reported by OECD, such government support for genomic medicine along with domestic biotech capabilities is expected to result in positive growth for automated gene synthesis services. An increase in the availability of biopharmaceutical start-ups is heralding promising new demand for scalable DNA synthesis, which they require for rapid prototyping and precision medicine pipelines.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 18.5% |
South Korea's advanced market in gene synthesis is now witnessing a rapid expansion, primarily due to the growing applications of mRNA therapeutics, gene editing, and microbial engineering. The Korean Bio economy 2030 Strategy has laid down the most important pillars for gene and cell therapies and is expected to drive investments in DNA synthesis infrastructure.
According to OECD, public-private partnerships are producing efficacious new solutions in synthetic biology, particularly with respect to cancer treatments, enzyme production, and vaccine development. Providing high-throughput synthesis capacity, developing customizable gene libraries for both academic and industrial users.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 19.2% |
The gene synthesis market expansion is constantly driven by the growth of synthetic biology and genetic engineering. These developments have created the demand for precise and efficient DNA synthesis solutions. The custom design of genes affords the synthesis of specific DNA sequences that allow researchers and companies to develop therapeutics, vaccines, and genetically modified organisms.
Among product type and end-user segments, custom gene synthesis, and biopharma companies have dominated worldwide market share due to their flexibility, scalability, and compliance with cutting-edge research and development projects.
These segments help in rapid prototyping of genetic constructs, support personalized medicine, and facilitate in general the advancement of biotechnology applications. With growing custom genetic requirements cutting across industries, custom gene synthesis services remain at the center of biotech and pharmaceutical companies' pursuits to innovate and meet complex biological challenges.
Custom gene synthesis dominates product use due to tailored DNA sequence creation, high fidelity, and support for diverse research applications
| Product Type | Market Share (2025) |
|---|---|
| Custom Gene Synthesis | 68.5% |
Custom gene synthesis leads the market by offering bespoke DNA sequences to meet specific research and development needs. This service allows the construction of genes with desired characteristics enabling advancement in areas like gene therapy, vaccine development, and synthetic biology.
Custom gene synthesis is the king of commercial DNA synthesis. It integrates high-precision genetic constructs, the rapid execution of days to weeks, and an alternative to inconvenient and laborious traditional cloning methods. Custom gene synthesis satisfies the need for rapid experimental initiation variable to different research avenues of life science.
Biotech & pharmaceutical companies dominate end user adoption due to extensive R&D activities, focus on novel therapeutics, and integration of synthetic biology techniques
| End User | Market Share (2025) |
|---|---|
| Biotech & Pharmaceutical Companies | 66.2% |
Biotech and pharmaceutical companies form the largest consumer segment in the gene synthesis market. It results from the quest to enhance drug discovery, therapy, and the development of diagnostics tools. Gene synthesis is therefore used in research and development and increases the speed of discovery and optimization of biologically active compounds.
Another factor supporting the choice of these companies is investments in advanced technologies and the demand for customized genetic materials to support complex research projects. As the demand for innovative healthcare solutions builds up, biotech and pharmaceutical companies are still at the front of gene synthesis technologies to advance medical science.
With the advancement of synthetic DNA usage in therapeutics, vaccine development, agriculture, diagnostics, and synthetic biology, the gene synthesis market is projected to grow. Rapid and accurate production of custom DNA sequences in large quantities would support CRISPR research, cell and gene therapy, and personalized medicine through gene synthesis and host systems.
Incremental improvements in throughput and cost-effectiveness have occurred through error correction, chip-based synthesis, and automation. Increased demand for codon optimization, modular genetic circuit design, and pathogen surveillance is facilitating faster entry into the market by the academic segment, pharmaceutical, and biotech segments.
Gene synthesis technology according to the WHO is considered one of the cornerstones in preparing for global bio surveillance and therapeutic readiness against any potential infectious disease threats.
Market Share Analysis by Key Players & Gene Synthesis Providers
| Company Name | Estimated Market Share (%) |
|---|---|
| Thermo Fisher Scientific | 14-17% |
| GenScript Biotech Corp. | 11-14% |
| Twist Bioscience | 9-12% |
| Integrated DNA Technologies (IDT) | 7-10% |
| Bioneer Corporation | 6-9% |
| Other Providers | 38-45% |
| Company Name | Key Offerings/Activities |
|---|---|
| Thermo Fisher Scientific | In 2024, expanded on-demand synthetic gene service with traceable GMP modules in 2025, launched customizable cDNA constructs for advanced cell engineering workflows. |
| GenScript Biotech Corp. | In 2024, introduced high-throughput gene synthesis with error correction for microbial and mammalian systems in 2025, added CRISPR-ready gene cassettes with AI-guided design. |
| Twist Bioscience | In 2024, scaled silicon-based gene writing capacity for genome-scale library assembly in 2025, rolled out secure synthesis protocols to support DNA data storage applications. |
| Integrated DNA Technologies (IDT) | In 2024, launched streamlined workflow from gene synthesis to gRNA production in 2025, enhanced turnaround speed for long gene constructs and dual promoter designs. |
| Bioneer Corporation | In 2024, offered plasmid-verified gene synthesis packages for diagnostics and vaccine development in 2025, upgraded backend for real-time order tracking and cloud integration. |
Key Market Insights
Thermo Fisher Scientific (14-17%)
Thermo Fisher, a major global company, provides complete synthetic DNA manufacturing solutions for research, clinical, and commercial applications. Examples of services offered by the various gene synthesis include codon optimization, sequence screening, and customizable vector integration-all of which aid in rapid prototyping in molecular biology and cell therapy. According to WHO, synthetic gene tools are crucial for improving vaccine platforms as well as in strengthening future pandemic preparedness.
GenScript Biotech Corp. (11-14%)
GenScript offers scalable gene synthesis for microbial, mammalian, and plant expression systems. It supports modular vector design, automated synthesis, and synthetic biology circuit construction for applications in immunotherapy, protein engineering, and diagnostics.According to UN , expanding synthetic biology capacity helps address global health, food security, and environmental sustainability.
Twist Bioscience (9-12%)
Twist Bioscience is known for its silicon-based synthesis platform that enables high-accuracy, high-throughput gene manufacturing. It caters to genome-wide screening, antibody development, and DNA-based data storage, with an emphasis on secure, scalable synthesis.According to OECD , platform technologies for writing and storing genetic information will be central to the future bioeconomy.
Integrated DNA Technologies (IDT) (7-10%)
IDT specializes in gene synthesis integrated with CRISPR and RNA design workflows. Its offerings support fast delivery, high-fidelity long sequences, and downstream compatibility with cell line engineering and gene expression studies.According to WHO, streamlined synthetic workflows reduce research cycle time and improve access to genetic tools in public health labs.
Bioneer Corporation (6-9%)
Bioneer offers customizable synthetic gene services with integrated plasmid delivery for diagnostics, vaccines, and synthetic constructs. Its cloud-based platform supports seamless order placement, tracking, and downstream cloning support. According to World Bank Report, enabling rapid and affordable access to genetic technologies promotes inclusive innovation in global biotechnology.
Other Key Players (38-45% Combined)
Numerous specialized providers and regional players contribute to innovation, affordability, and application-specific synthesis. These include:
The overall market size for the gene synthesis market was approximately USD 1,089.3 million in 2025.
The gene synthesis market is expected to reach approximately USD 6,203.6 million by 2035.
The demand for gene synthesis is rising due to increasing adoption of synthetic biology techniques, advancements in DNA synthesis technologies, and growing applications in drug discovery.
The top 5 countries driving the development of the gene synthesis market are the United States, China, Germany, Japan, and the United Kingdom.
Custom gene synthesis services and adoption by biotech & pharmaceutical companies are expected to command significant shares over the assessment period.
Explore Life Science & Biotechnology Insights
Gene Synthesis Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
